Global In Vitro Diagnostics Markets Outpace Pharma Industry Growth, finds Frost & Sullivan
-- Rapidly expanding Asia-Pacific market is a focus area of every IVD company's long-term strategy
MOUNTAIN VIEW, California, June 6, 2013 /PRNewswire/ -- Despite global economic and industry challenges, in vitro diagnostics (IVD) markets are growing robustly at double the rate of the global pharmaceutical industry in some segments. Growth in emerging markets and next-wave emerging markets, particularly in the Asia-Pacific (APAC) region, are the most important factors in formulating future strategies.
New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com) Analysis of the Global In Vitro Diagnostics Market research finds the market size was $45.68 billion in 2012 and forecasts revenue to reach $64.65 billion in 2017. While the U.S. and Western Europe are the largest IVD markets, APAC and Eastern Europe are projected to be the fastest growing. The research covers immunochemistry, clinical microbiology, tissue diagnostics, hemostasis, hematology, molecular diagnostics, self-monitoring blood glucose (SMBG), and point of care testing (POCT) segments.
For more information on this research, please email Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
"The APAC region holds the greatest number of next wave emerging markets, such as Indonesia, Vietnam and the Philippines," noted Frost & Sullivan Senior Industry Analyst Winny Tan, Ph.D. "This fast rising regional market must be part of every IVD company's long-term strategy."
APAC healthcare expenditure is forecast to increase 151 percent by 2020. The demand for better quality healthcare and healthcare infrastructure development will drive strong demand for IVD in the region.
The largest markets continue to be the U.S. and Western Europe, which collectively represent nearly 60 percent of the global IVD market. The anticipated outcome for these markets, however, varies.
"Unfavorable business conditions for IVD are slowing the U.S. market, forcing market participants to pursue outside markets that are demonstrating rapid growth," remarked Tan. "On the other hand, despite challenges in reimbursement and a need for Conformite Europeenne (CE) marking reform, Western European markets exhibit an upward trajectory."
Such optimism will, however, be tempered by lower public health reimbursement in Western Europe and Medicare cuts in the United States. This will restrain demand across all segments of the IVD market in those regions.
"Such trends will act as a further spur for competitive IVD companies who have long recognized slowing growth in developed nations and have pursued emerging markets and other strategies," said Tan. "Global IVD market participants will employ a diverse set of strategies rather than rely on comprehensive product portfolios to expand their businesses."
Analysis of the Global In Vitro Diagnostics Market is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: Analysis of the Asia-Pacific Molecular Diagnostics Market, U.S. qPCR Reagents Market, Overview of the In-vitro Diagnostics Market in India, and Analysis of the European Hepatitis B and C Therapeutics Markets. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare, and LinkedIn, for the latest news and updates.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Analysis of the Global In Vitro Diagnostics Market
NC19-52
Contact:
Britni Myers
Corporate Communications -- North America
P: +1-210-477-8481
F: +1-210-348-1003
E: britni.myers@frost.com
Twitter: @Frost_Sullivan
Facebook: Frost & Sullivan
Share this article